Bourla chooses BD over buybacks in 2020
CEO Albert Bourla outlined his vision for the new innovative business that will emerge from Pfizer after the spin-off of Upjohn, saying that the company would invest in business development and pipeline growth rather than pursue buybacks in 2020.
“The past was a very different Pfizer. The past had to deal with declining revenues, constant declining revenues,” Bourla said on the company’s 2019 earnings call. “Now is a very